Ito, Kyoko http://orcid.org/0000-0003-3258-4429
Akizawa, Tadao http://orcid.org/0000-0002-6150-9201
Arita, Kojo
Mitobe, Yuko
Komatsu, Norio http://orcid.org/0000-0003-1880-9126
Article History
Received: 4 October 2023
Accepted: 27 December 2023
First Online: 25 February 2024
Change Date: 6 April 2024
Change Type: Update
Change Details: The original version is updated as the author would like to replace the Fig 2b.
Declarations
:
: TA and NK received consulting fees from TORII and JT. TA received consulting fees from GlaxoSmithKline K.K., Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Bayer Yakuhin Ltd., Kissei Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., and lecture fees from Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Bayer Yakuhin Ltd., Kissei Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co. Ltd and Mitsubishi Tanabe Pharma Corporation. NK is a board member of PharmaEssentia Japan KK (Tokyo, Japan), KI and YM are employees of TORII, and KA is an employee of JT.
: All study participants provided written informed consent before undergoing any study procedures.
: This study was performed in accordance with the Declaration of Helsinki and ethical guidelines. The study protocol was approved by the institutional review boards.